CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 05 2025
0mins
Source: Globenewswire
Company Overview and Achievements: CytoMed Therapeutics Limited, a biopharmaceutical company based in Singapore and Malaysia, focuses on developing affordable immune cell therapies for cancer and autoimmune diseases. In 2024, they achieved significant growth, became a clinical stage biopharma with the ANGELICA trial, acquired a licensed cord blood bank, and initiated strategic partnerships in China and India.
Future Plans and Strategic Direction: Looking ahead to 2025, CytoMed aims to enhance its presence in the US, submit an FDA IND for their gamma delta T cells, and explore revenue-generating methods for late-stage patients through partnerships and investments in clinics, while maintaining financial prudence following a modest IPO.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
